Filtros de búsqueda

Lista de obras de Christos Chouaid

1565PLUNG CANCER IN PATIENTS UNDER 40 YEARS: A PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY (GROUPE FRANÇAIS DE PNEUMO-CANCÉROLOGIE (GFPC) 1001 STUDY)

3062 Ceritinib following crizotinib in ALK-positive (+) advanced NSCLC patients (pts): Results from the French Temporary Authorization for Use (ATU) experience

article

3105 Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial

9076 POSTER An Interim Analysis of Health-Related Quality of Life (HRQoL) in Patients With Non-Squamous Non-Small-Cell Lung Cancer (nsNSCLC) Receiving Bevacizumab Vs Bevacizumab+Pemetrexed for Maintenance Therapy in AVAPERL 1

article

9164 An indirect comparison of the efficacy of bevacizumab plus cisplatin and gemcitabine (BCG) or bevacizumab plus carboplatin and paclitaxel (BCP) versus pemetrexed plus cisplatin (PC) and cetuximab plus vinorelbine and cisplatin (CVC) in patients

A Web-Based Delphi Study on the Indications of Chest Radiographs for Patients in ICUs

scientific article published on 07 November 2007

A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France

artículo científico

A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.

artículo científico publicado en 2011

A multicenter phase II randomized study of docetaxel (D)/gemcitabine (G) weekly followed by erlotinib (E) after progression versus erlotinib followed by docetaxel/gemcitabine after progression in advanced non-small cell lung cancer (NSCLC) in fit eld

A multicenter phase II randomized study of gemcitabine (G) weekly followed by erlotinib (E) after progression versus E followed by G after progression in advanced non-small cell lung cancer (NSCLC) in vulnerable elderly patients selected with a compr

A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the

artículo científico publicado en 2012

A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (t

artículo científico publicado en 2011

A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer

artículo científico publicado en 2014

A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer

artículo científico publicado en 2010

A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer

artículo científico publicado en 2015

A randomized phase II trial assessing in advanced non-small cell lung cancer patients with stable disease after two courses of cisplatin-gemcitabine an early modification of chemotherapy doublet with paclitaxel-gemcitabine versus continuation of cis

artículo científico publicado en 2009

A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective

artículo científico publicado en 2015

A severe side effect of antitubercular therapy: pyrazinamide induced thrombocytopenia

artículo científico publicado en 2008

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

artículo científico publicado en 2015

Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study

article

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

artículo científico publicado en 2015

An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.

artículo científico publicado en 2011

An open multicenter phase II trial of docetaxel–gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): The GFPC 02-02a study

artículo científico publicado en 2007

An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study

artículo científico publicado en 2007

An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer

artículo científico publicado en 2013

Analyse médico-économique des métastases osseuses des cancers broncho-pulmonaires

artículo científico publicado en 2006

Analyse économique de deux chimiothérapies en première ligne du cancer pulmonaire à un stade avancé

artículo científico publicado en 2006

Analysis of health economics assessment reports for pharmaceuticals in France - understanding the underlying philosophy of CEESP assessment

artículo científico publicado en 2017

Anti PD-1 (nivolumab, pembrolizumab) or anti PD-L1 (atezolizumab) versus docetaxel for previously treated patients with advanced NSCLC: A meta-analysis

Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial

artículo científico publicado en 2018

Are Systemic Manifestations Ascribable to COPD in Smokers? A Structural Equation Modeling Approach.

artículo científico publicado en 2018

Association between lung cancer somatic mutations and occupational exposure in never-smokers

artículo científico publicado en 2017

Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab

scientific article published on 10 August 2020

Author’s Reply to Arnaud Uguen: “Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study)”

article

Beclin1 circulating levels and accelerated ageing markers in COPD

article

Beclin1 circulating levels and accelerated aging markers in COPD.

artículo científico publicado en 2018

Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE).

artículo científico publicado en 2017

Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.

artículo científico publicado en 2015

Bevacizumab in combination with first-line treatment for metastatic non-small cell lung cancer in clinical practice. Results of the EOLE study

artículo científico publicado en 2016

Brief Report: Phase 2 Study of the HSP-90 inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.

artículo científico publicado en 2017

Burden of Disease And Management of Mesothelioma In France: A National Cohort Analysis

article

CPAP titration by an auto-CPAP device based on snoring detection: a clinical trial and economic considerations.

artículo científico publicado en 1998

Characteristics of Lung Cancer in Patients Younger than 40 Years: A Prospective Multicenter Analysis in France

article

Choriocarcinoma with pulmonary metastasis: diagnosis and treatment

artículo científico publicado en 2009

Chronic bronchitis in the general population: Influence of age, gender and socio-economic conditions

artículo científico publicado en 2011

Clinical burden caused by hospitalization for febrile neutropenia in France in 2010-2011: An analysis of the PMSI database

artículo científico publicado en 2016

Clinical efficacy and cost-effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration for preoperative staging of non-small-cell lung cancer: Results of a French prospective multicenter trial (EVIEPEB)

artículo científico publicado en 2019

Companion Diagnostics-Targeted Therapies Pairings Model-Based Economic Evaluation: Reflection On A General Modeling Framework And Key Methodological Points

article

Comparison of four demand oxygen delivery systems at rest and during exercise for chronic obstructive pulmonary disease

artículo científico publicado en 2004

Comparison of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (Esmo-Mcsb) and the American Society of Clinical Oncology (Asco) Framework for Assessing Value in Cancer Care

Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain.

artículo científico publicado en 2011

Conséquences de la prophylaxie spécifique sur le diagnostic de pneumocystose pulmonaire chez les sujets infectés par le VIH

artículo científico publicado en 1993

Corrigendum to “Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study”

scholarly article published in Lung Cancer

Cost analysis of adverse events associated with non-small cell lung cancer management in France

artículo científico

Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505).

artículo científico publicado en 2012

Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)

artículo científico publicado en 2012

Cost effectiveness of the induced sputum technique for the diagnosis of Pneumocystis carinii pneumonia (PCP) in HIV-infected patients

scientific article published on 01 February 1993

Cost of lung cancer: a methodological review.

artículo científico publicado en 2006

Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers

artículo científico publicado en 2017

Cost-Effectiveness of Second-Line Chemotherapy for Non-small Cell Lung Cancer: An Economic, Randomized, Prospective, Multicenter Phase III Trial Comparing Docetaxel and Pemetrexed: The GFPC 05-06 Study ⬇️

artículo científico publicado el 1 de enero de 2011

Cost-analysis of four diagnostic strategies for Pneumocystis carinii pneumonia in HIV-infected subjects

scientific article published on 01 September 1995

Cost-benefit analysis of a simulated institution-based preoperative smoking cessation intervention in patients undergoing total hip and knee arthroplasties in France

artículo científico publicado en 2008

Cost-effectiveness analysis of afatinib vs gefitinib in EGFR-Mutated population with advanced non-small-cell lung cancer

article

Cost-effectiveness analysis of afatinib vs gefitinib in EGFR-mutated population with advanced non-small-cell lung cancer

Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France

article

Cost-effectiveness of afatinib versus erlotinib for the treatment of squamous non-small cell lung cancer in france after a first-line platinum based therapy

article

Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3.

artículo científico publicado en 2011

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study

artículo científico publicado en 2014

Costs of Adverse Events Associated with Cancer Therapies in Non-Small Cell Lung Cancer in France

article

Costs of COPD in France: A National Database Analysis

article

Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of 5550 Exons Sequenced by 15 Molecular French Laboratories (Evaluation of the EGFR Mutation Status f

article

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer

artículo científico publicado en 2012

Current Process and Future Path for Health Economic Assessment of Pharmaceuticals in France

artículo científico publicado en 2015

Current process and future path for health economic assessment of pharmaceuticals in France

artículo científico publicado en 2015

Cutaneous lymphangitis carcinomatosa in a patient with lung adenocarcinoma: case report and literature review

artículo científico publicado en 2012

Delays for diagnosis and treatment of lung cancers: a systematic review

artículo científico publicado en 2014

Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis.

artículo científico publicado en 2018

Diagnosis of nosocomial pneumonia in medical ward: repeatability of the protected specimen brush.

artículo científico publicado en 2001

Diagnosis of tuberculous uveitis: clinical application of an interferon-gamma release assay

artículo científico publicado en 2011

Duration of nivolumab for pretreated, advanced non-small-cell lung cancer

artículo científico publicado en 2020

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

artículo científico publicado en 2018

EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients

artículo científico publicado en 2015

Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.

artículo científico publicado en 2016

Economic analyses of immune-checkpoint inhibitors to treat lung cancer

artículo científico publicado en 2020

Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS)

article

Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review

artículo científico publicado en 2014

Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis

artículo científico publicado en 2007

Economic impact of second- and third-line erlotinib treatment of non small-cell lung cancer

artículo científico publicado en 2008

Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy

artículo científico publicado en 2009

Economics of treatments for non-small cell lung cancer

artículo científico publicado en 2009

Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer

article

Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer

artículo científico publicado en 2010

Effects of polycythemia on systemic endothelial function in chronic hypoxic lung disease

scientific article published on 20 January 2011

Efficacy and toxicity of mitomycin, ifosfamide, and cisplatin (MIP) in patients with inoperable non-small cell lung cancer.

artículo científico publicado en 1996

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with <i>BRAF</i> V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019

artículo científico publicado en 2020

Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors

artículo científico publicado en 2018

Efficacy of next treatment received after Nivolumab (Nivo) progression in patients (pts) with non-small-cell lung cancer (NSCLC)

article

Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer.

artículo científico publicado en 2018

Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study

artículo científico publicado en 2013

Empyema of the thorax due to Gemella haemolysans

artículo científico publicado en 1999

Epidemiology and Treatment Costs of Bone Metastases from Lung Cancer: A French Prospective, Observational, Multicenter Study (GFPC 0601) ⬇️

artículo científico publicado el 1 de marzo de 2011

Epidemiology, management and cost of bone metastases from lung cancer

artículo científico publicado en 2013

Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France

artículo científico publicado en 2017

Expected Impact of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (Esmo-Mcsb) on Health Technology Assessment

article

Factors associated with excessively lengthy treatment of tuberculosis in the eastern Paris region of France in 2004.

artículo científico publicado en 2010

Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01).

artículo científico publicado en 2014

First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors

scientific article published on 01 April 2019

First-line immune-checkpoint inhibitor plus chemotherapy <i>versus</i> chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis

artículo científico publicado en 2020

First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study

scientific article published on 05 February 2020

French Health Technology Assessment Of Antineoplastic Drugs Indicated In The Treatment Of Solid Tumours: Perspective For Future Trends

artículo científico publicado en 2015

French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends.

artículo científico publicado en 2016

Frequency of comorbidities in chronic obstructive pulmonary disease, and impact on all-cause mortality: A population-based cohort study

artículo científico publicado en 2016

Geriatric AIDS (6 years after pneumonectomy). Apropos of a case

artículo científico publicado el 1 de enero de 1991

Grippe aviaire

artículo científico publicado en 2008

Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting

artículo científico publicado en 2013

Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089).

artículo científico publicado en 2013

Hospital admissions related to acute exacerbations of chronic obstructive pulmonary disease in France, 1998-2007.

artículo científico publicado en 2010

Imbalance between Platelet Vascular Endothelial Growth Factor and Platelet-derived Growth Factor in Pulmonary Hypertension

artículo científico publicado en 2000

Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review

article published in 2018

Immunothérapie : un nouveau paradigme dans la prise en charge du cancer bronchique non à petites cellules

Impact médico-économique du cancer du poumon

Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study.

artículo científico publicado en 2015

Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small-Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study)

scientific article published on 30 December 2020

Impact of Therapy Persistence on Exacerbations and Resource Use in Patients Who Initiated COPD Therapy

artículo científico publicado en 2019

Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small–cell lung cancers: An open phase II study using concurrent cisplatin–oral vinorelbine and radiotherapy (GFPC 08-06)

artículo científico publicado en 2018

Impact of a multidisciplinary approach to the control of antibiotic prescription in a general hospital.

artículo científico publicado en 2003

Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).

artículo científico publicado en 2012

Impaired Humoral and Cellular Immune Responses to Influenza Vaccination in COPD Patient

artículo científico publicado en 2017

Increased erythropoietin synthesis in patients with COLD or left heart failure is related to alterations in renal haemodynamics

artículo científico publicado en 2001

Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01.

artículo científico publicado en 2015

Infectious complications associated with the use of immune checkpoint inhibitors in oncology: Reactivation of tuberculosis after anti PD-1 treatment

artículo científico publicado en 2017

Interactions between HIV infection and chronic obstructive pulmonary disease: Clinical and epidemiological aspects

artículo científico publicado en 2011

Interleukin-6 gene polymorphism confers susceptibility to pulmonary hypertension in chronic obstructive pulmonary disease.

artículo científico publicado en 2006

Interstitial Lung Disease Associated with Lung Cancer: A Case-Control Study

artículo científico publicado en 2020

Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases.

artículo científico publicado en 2017

Intrathoracic extrapulmonary pneumocystis. 3 cases in HIV positive patients

artículo científico publicado el 24 de octubre de 1992

Is Oncology Drug Financial Toxicity A Specific Us Issue?

article

Isolated 5' Signals Are an Atypical Pattern To Be Considered as Positive for ALK Rearrangement: A Brief Report of Three Cases and Review of the Literature

La lutte antituberculeuse en France : évaluation des pratiques par un groupe de travail de la SPLF auprès des services de lutte antituberculeuse

article

Le dépistage du cancer bronchopulmonaire par tomodensitométrie thoracique à faible dose en France : enjeux et perspectives

article

Les corticoïdes inhalés dans l’asthme : analyse médico-économique des essais cliniques

artículo científico publicado en 2008

Les exacerbations de l’asthme de l’adulte en questions

artículo científico publicado en 2010

Les indicateurs médico-économiques et l’innovation en oncologie thoracique

article

Lung cancer and interstitial lung disease: a literature review

Lung cancer survivors and employment: A systematic review

scientific article published on 11 March 2019

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives

artículo científico publicado en 2013

Machine Learning–Based Analysis of Treatment Sequences Typology in Advanced Non–Small-Cell Lung Cancer Long-Term Survivors Treated With Nivolumab

artículo científico publicado en 2022

Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.

artículo científico publicado en 2014

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe

artículo científico publicado en 2012

Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study

Management and outcome of French elderly patients with lung cancer: an IFCT survey

article

Management and treatment outcomes of tuberculous patients, eastern Paris, France, 2004.

artículo científico publicado en 2009

Management of malignant pericardial effusion in lung cancer

artículo científico publicado en 2014

Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study).

artículo científico publicado en 2015

Management of nosocomial pneumonia on a medical ward: a comparative study of outcomes and costs of invasive procedures.

artículo científico publicado en 2009

Management of patients with head and neck cancer (HNC) and synchronic stage I or II lung cancer. SYNCHRON GFPC 15-01 study

Modeling the critical care demand and antibiotics resources needed during the Fall 2009 wave of influenza A(H1N1) pandemic.

artículo científico publicado en 2009

Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study

artículo científico publicado en 2013

Multicentric phase II trial of cisplatin/etoposide chemotherapy in advanced large-cell neuroendocrine carcinoma of the lung (LCNEC): Study GFPC 03-02 from the Groupe Francais de Pneumo-cancerologie

Multidimensional analyses to assess the relations between treatment choices by physicians and patients' characteristics: the example of COPD.

artículo científico publicado en 2012

New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab

artículo científico publicado en 2018

Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study)

scientific article published on 26 October 2020

Nivolumab-refractory patients with advanced non-small-cell lung cancer

artículo científico publicado en 2019

Non small cell lung cancer (NSCLC) patients harboring BRAF mutation: Clinical characteristics and management in real world setting. Cohort BRAF EXPLORE GFPC 02-14

Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02-14

artículo científico publicado en 2019

Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study).

artículo científico publicado en 2017

Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study).

artículo científico publicado en 2015

O-060 Routine once-weekly darbepoetin alfa administration is cost-effective in lung cancer patients with chemotherapy-induced anemia: A Markov analysis

O-091 A randomized phase II trial of docetaxel alone and in combinationwith gefitinib (IRESSA) as second-line therapy for patients with non-small-cell lung cancer

Observational study of patients with non-small cell lung cancer (NSCLC) treated by erlotinib: Clinical practices and main outcomes in France (OBSTAR)

article

Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study).

artículo científico publicado en 2018

Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage-IV non-small-cell lung cancer - VinMetAtezo trial, (GFPC‡ 04-2017)

scientific article published on 02 January 2020

Optimization of small-cell lung cancer chemotherapy with heparin: a comprehensive retrospective study of 239 patients treated in a single specialized center.

artículo científico publicado en 2011

Oral second- and third-line lomustine-etoposide-cyclophosphamide chemotherapy for small cell lung cancer.

artículo científico publicado en 2009

Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic review

artículo científico publicado en 2018

Organisation de la lutte anti-tuberculeuse : la mobilisation des pneumologues

artículo científico publicado en 2004

Organization of intensive care in situation of avian flu pandemic

artículo científico publicado en 2008

Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis

artículo científico publicado en 2012

P66 A multicenter phase II randomized study of docetaxel/gemcitabine weekly followed by erlotinib after progression versus erlotinib followed by docetaxel/gemcitabine after progression in advanced non small cell lung cancer (NSCLC) in fit elderly pat

scholarly article by H. Le Caer et al published October 2009 in Critical Reviews in Oncology Hematology

PCN10 INCREMENTAL COST-EFFECTIVENESS RATIO OF DARBEPOETIN ALFA (ARANESP®) IN THE TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA IN LUNG CANCER PATIENTS

PCN109 Cost Effectiveness of First Line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: A Markov Model

PCN110 Health-Related Quality of Life in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

artículo científico

PCN125 AN ECONOMICAL, RANDOMIZED, MULTICENTER PHASE III TRIAL OF SECOND LINE TREATMENT FOR NON SMALL CELL LUNG CANCER (NSCLC) COMPARING DOCETAXEL VERSUS PEMETREXED: GFPC (GROUPE FRANÇAIS DE PNEUMO-CANCÉROLOGIE) 05–06 STUDY

article published in 2009

PCN126 OVERVIEW OF PRIMARY ENDPOINTS, PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) FOR NON-SMALL CELL LUNG CANCER (NSCLC): THEIR VALUE IN TREATMENT DECISIONS AND PATIENT CARE

article published in 2011

PCN13 REAL LIFE OUTCOMES IN 2ND LINE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A PILOT STUDY IN FRANCE AND GERMANY ANALYSING ERLOTINIB VERSUS CHEMOTHERAPY

article

PCN14 AN INDIRECT COMPARISON OF THE EFFICACY OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) OR BEVACIZUMAB PLUS CARBOPLATIN AND PACLITAXEL (BCP) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQU

PCN16 MIXED TREATMENT COMPARISON OF BEVACIZUMAB-BASED THERAPIES RELATIVE TO DOUBLET-CHEMOTHERAPY COMBINATIONS TO ESTIMATE THE RELATIVE EFFICACY IN PROGRESSION-FREE SURVIVAL FOR TREATMENT OF FIRST-LINE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

article

PCN161 REIMBURSEMENT OF ADMINISTRATION COSTS ARE UNAFFECTED BY SINGLE, DOUBLE OR TRIPLE ANTI-CANCER THERAPY COMBINATIONS IN THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) IN FRANCE AND GERMANY

article

PCN21 FIRST-LINE BEVACIZUMAB-BASED THERAPY VERSUS PEMETREXED + CISPLATIN FOR THE TREATMENT OF ADVANCED ADENOCARCINOMA NONSQUAMOUS NON-SMALL CELL LUNG CANCER: INDIRECT COMPARISON APPLYING REAL-LIFE OUTCOMES

PCN3 ECONOMIC IMPACT OF SECOND- ANDTHIRD-LINE ERLOTINIB TREATMENT OF NON SMALL-CELL LUNG CANCER:A FRENCH OBSERVATIONAL STUDY

article

PCN37 Cost-Minimization Analysis of Second-Line Chemotherapy for Non-Small-Cell Lung Cancer (NSCLC)

PCN42 Treatment Costs of Bone Metastases in Patients with Lung Cancer: Results From A French Prospective, Observational, Multicenter Study (GFPC 0601)

article

PCN43 THE COST OF TREATING GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE

article

PCN67 LOWER ADMINISTRATION COSTS OF BEVACIZUMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY VERSUS CETUXIMAB-VINORELBINE-CISPLATIN THERAPY FOR THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) FOCUSING ON THREE EUROPEAN HEALTH CARE

article

PCN79 Cost Effectiveness of Erlotinib in First Line Treatment of Advanced Non Small Cell Lung Cancer (NSCLC) in Vulnerable Elderly Patients: An Economical Analysis of a prospective Phase 2 Study (GFPC 0505)

PCN8 REAL LIFE OUTCOMES IN 1ST LINE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): A PILOT STUDY IN FRANCE AND GERMANY ANALYSING BEVACIZUMAB-BASED VERSUS NON-BEVACIZUMAB-BASED TREATMENTS

article

PCN81 COST-EFFECTIVENESS ANALYSIS OF THREE STRATEGIES OF ERLOTINIB TREATMENT IN NON0-SMALL-CELL LUNG CANCER:A PROSPECTIVE MULTICENTRIC FRENCH STUDY (ERMETIC)

article

PCN84 COST-EFFECTIVENESS OF ERLOTINIB IN FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FIT ELDERLY PATIENTS: AN ECONOMICAL ANALYSIS OF A PROSPECTIVE PHASE 2 STUDY (GFPC 0504)

PCN9 From Indirect Evidence to Direct Evidence: A Real-World Example for the Value of Indirect Treatment Comparisons in Second-Line NSCLC Therapy

article

PCN9 OBSERVATIONAL STUDY OF PATIENTS WITH NON SMALL CELL LUNG CANCER (NSCLC) TREATED BY ERLOTINIB: CLINICAL PRACTICES AND MAIN OUTCOMES IN FRANCE

article

PCN92 VALUE OF ALOPECIA FOR LUNG CANCER PATIENT TREATED BY SECOND LINE CHEMOTHERAPY: A WILLINGNESS TO PAY STUDY

PCN94 HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN 1ST LINE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS IN A REAL LIFE SETTING: BEVACIZUMAB-BASED VERSUS NON-BEVACIZUMAB BASED THERAPY IN A EUROPEAN PILOT STUDY

article

PCN97 COST EFFECTIVENESS OF ERLOTINIB TREATMENT GIVEN BY A CLINICALLY BASED APPROACH AND AN EGFR/KRAS TESTING-GUIDED APPROACH ADVANCED IN NON SMALL-CELL LUNG CANCER: A PROSPECTIVE MULTICENTRIC FRENCH STUDY (ERMETIC)

article

PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" study

artículo científico publicado en 2020

PD4-3-7: Multicentric phase II trial of Cisplatin plus Etoposide chemotherapy in advanced Large-Cell Neuro Endocrine Carcinoma of the Lung (LCNEC): preliminary results. Study 03-02 from the “Groupe Francais de Pneumo-Cancerologie (GFPC)

scholarly article by Jacques Le Treut et al published August 2007 in Journal of Thoracic Oncology

PD6-3-3: Medical and economical impact of bone metastases in lung cancer patients: a prospective French national, multicentric study (GFPC 06-01 study)

article

PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION.

artículo científico publicado en 2017

PRS19 Quality of Life and Economics of Asthma Control in France and Spain: Final Results of the EU-Coast Study

article

PRS46 Effectiveness and Cost-Utility Estimates of Tiotropium Treatment and Pulmonary Rehabilitation Programs in French Patients with Chronic Obstructive Pulomonary Disease

article

PRS9 QUALITY OF LIFE AND ECONOMIC IMPACT OF ASTHMA CONTROL IN FRANCE AND SPAIN. FIRST RESULTS OF THE EU-COAST STUDY

article

Patient (Pt) and caregiver (Cg) perspectives in non-small cell lung cancer (NSCLC)

Patient preference for chronic obstructive pulmonary disease (COPD) treatment inhalers: a discrete choice experiment in France

scientific article published on 15 February 2019

Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units.

artículo científico publicado en 2014

Patients with non-small-cell lung cancer harbouring a BRAF mutation: a multicentre study exploring clinical characteristics, management, and outcomes in a real-life setting: EXPLORE GFPC 02-14

artículo científico publicado en 2018

Perception of alopecia by patients requiring chemotherapy for non-small-cell lung cancer: a willingness to pay study

artículo científico publicado en 2010

Polycythemia impairs vasodilator response to acetylcholine in patients with chronic hypoxemic lung disease.

artículo científico publicado en 1998

Prise en charge des métastases cérébrales des cancers du poumon

Prise en charge des métastases rachidiennes de cancer bronchopulmonaire

artículo científico publicado en 2013

Prise en charge et coûts de la bronchopneumopathie chronique obstructive en France en 2011

article

Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group

artículo científico publicado en 2017

Pulmonary artery smooth muscle cell senescence is a pathogenic mechanism for pulmonary hypertension in chronic lung disease

artículo científico publicado en 2011

Pulmonary cryptosporidiosis in the acquired immunodeficiency syndrome

artículo científico publicado en 1996

Pulmonary toxoplasmosis in HIV-infected patients: usefulness of polymerase chain reaction and cell culture

artículo científico publicado en 1995

Qualité de vie et traitement de l’anémie chimio-induite dans le cancer bronchopulmonaire : étude prospective

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

artículo científico publicado en 2008

Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study

artículo científico publicado en 2014

Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.

artículo científico publicado en 2012

Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients.

artículo científico publicado en 2018

Reply to N. Singh et al.

artículo científico publicado en 2013

Reply to R.D. Nipp et al, M.-J. Molina-Garrido et al, and A. Gajra et al

artículo científico publicado en 2016

Review of economic analyses of treatment for non-small–cell lung cancer (NSCLC)

article

Role for interleukin-6 in COPD-related pulmonary hypertension

artículo científico publicado en 2009

Routine once-weekly darbepoetin alfa administration is cost-effective in lung cancer patients with chemotherapy-induced anemia: a Markov analysis

artículo científico publicado en 2006

Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model

artículo científico publicado en 1998

Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies

Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC

artículo científico publicado en 2018

Second-Line Oral Chemotherapy (Lomustine, Cyclophosphamide, Etoposide) Versus Intravenous Therapy (Cyclophosphamide, Doxorubicin, and Vincristine) in Patients With Relapsed Small Cell Lung Cancer: A Randomized Phase II Study of GFPC 0501

artículo científico publicado en 2014

Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study

Second-line treatments of small-cell lung cancers

artículo científico publicado en 2017

Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease

artículo científico publicado en 2009

Simulation and Comparison of Progression-Free Survival (Pfs) Among Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Receiving Sequential Therapy

Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy

artículo científico

Simulation-Based Estimates of the Effectiveness and Cost-Effectiveness of Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease in France

artículo científico publicado en 2016

Simulation-based estimates of effectiveness and cost-effectiveness of smoking cessation in patients with chronic obstructive pulmonary disease

artículo científico publicado en 2011

Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC).

artículo científico publicado en 2010

Soins de support en oncologie thoracique : une nouvelle série de la Revue

scientific article published on 01 February 2013

Standardized Protocol Improves Asthma Management in Emergency Department

artículo científico publicado en 2004

Study ESOGIA-GFPC 08-02: Phase III, randomized, multicenter trial involving subjects over age 70 with stage IV non-small cell lung cancer and comparing a “classical” strategy of treatment allocation (dual-agent therapy based on carboplatin or mon

Surgical pulmonary biopsies in patients with HIV infection: results apropos of a series of 21 cases

artículo científico publicado en 1997

Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study).

artículo científico

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial

artículo científico publicado en 2015

TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial.

artículo científico publicado en 2015

TIME, a Phase 2b/3 Study Evaluating TG4010 in Combination With First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 2b Results

Targeted Therapies in Non–Small-Cell Lung Cancer Management: No Cost-Effective Strategies?

artículo científico publicado en 2014

Targeted therapy for localized non-small-cell lung cancer: a review

artículo científico publicado en 2016

Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.

artículo científico publicado en 2017

The American Society of Clinical Oncology (Asco) Net Health Benefit (Nhb) Assessment Tool: Which Implications for Value Assessment of Cancer Therapies?

article

The association between asthma control, health care costs, and quality of life in France and Spain

artículo científico publicado en 2013

The costs of asthma in France and the economic implications of its level of control

artículo científico publicado en 2011

The costs of asthma in France: an economic analysis by a Markov model

artículo científico publicado en 2004

The organisation of intensive care in a situation of pandemic avian influenza

artículo científico publicado en 2008

Traitement adjuvant des cancers bronchiques non à petite cellules : tolérance de l’association platine-pemetrexed

artículo científico publicado en 2013

Treatment of lung cancer: will financial issues become a criterion of choice?

artículo científico publicado en 2013

Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study

scientific article published on 30 April 2020

Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents

artículo científico publicado en 2013

Use of the Polymerase Chain Reaction Technique on Induced-Sputum Samples for the Diagnosis ofPneumocystis cariniiPneumonia in HIV-infected Patients:A Clinical and Cost-Analysis Study

article

Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies

scientific article published on 01 July 2000

Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review

artículo científico publicado en 2011

What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?--Results from the lung cancer economics and outcomes research (LUCEOR) study.

artículo científico publicado en 2013

Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study

artículo científico publicado en 2010

[A prospective study of quality of life and treatment of chemotherapy-induced anaemia in lung cancer]

artículo científico publicado en 2007

[Allopurinol hypersensitivity. A possible cause of hepatitis and mucocutaneous eruptions in a patient undergoing antitubercular treatment]

scientific article published on 01 January 1995

[Asthma]

artículo científico publicado en 2002

[Can positron emission tomography assessment of response to treatment help to individualize use of erlotinib in non-small cell lung cancer?]

artículo científico publicado en 2016

[Can the medical-social and administrative organization improve the individual and collective management of tuberculosis in France?]

artículo científico publicado en 2004

[Chemotherapy at the end of life for patients with lung cancer. A practice analysis].

artículo científico publicado en 2014

[Concordance between two variables: numerical approaches (qualitative observations - the kappa coefficient-; quantitative measures].

artículo científico publicado en 2004

[Cost-effectiveness of darbepoetin alpha in an every-3-weeks schedule]

artículo científico publicado en 2008

[Effect of tinzaparin on survival in non-small-cell lung cancer after surgery. TILT: tinzaparin in lung tumours]

artículo científico publicado en 2011

[Hospital readmissions for asthma: an indicator of health system performance]

artículo científico publicado en 2009

[Impact of a multidisciplinary approach for monitoring prescribing of antibiotics in a hospital].

artículo científico publicado en 1998

[Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement].

artículo científico publicado en 2016

[Management of COPD according to severity by respiratory specialists in France]

artículo científico publicado en 2009

[Markov models in clinical medicine]

scientific article published on 01 November 2004

[Organization of intensive care units, in case of pandemic avian flu].

artículo científico publicado en 2007

[Pulmonary infections with Mycobacterium xenopi in patients without HIV infection]

artículo científico publicado en 2007

[Quality and accreditation in health establishments. Application of experience acquired in the industrial setting]

scientific article published on 01 January 1998

[Respiratory tract infectious pathologies]

artículo científico publicado en 2002

[Supportive cares on thoracic oncology]

artículo científico publicado en 2012

[Validation of an evaluation questionnaire for COPD acute exacerbations (Exascore)].

artículo científico publicado en 2015

Épidémiologie de la tuberculose en France, hors métropole : enjeux et perspectives

article

Étude de phase 2, randomisée, évaluant une polychimiothérapie orale (CCNU, Cyclophosphamide, étoposide) et une polychimiothérapie intraveineuse dans les cancers bronchiques à petites cellules en seconde ligne en rechute (essai GFPC0501)

scientific article published on 01 May 2007

Évaluation de la qualité des soins en pneumologie : enjeux et perspectives

scientific article published on 01 October 2007

Évaluation de la ventilation non invasive préopératoire avant chirurgie de résection pulmonaire. Étude préOVNI GFPC 12-01

artículo científico publicado en 2012

Évaluation gériatrique et morbidité après exérèse pulmonaire pour cancer bronchique

scientific article published on 01 May 2010

“Regards Croisés 2009”: French survey about perception and management of fatigue-related cancer

article

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda